Axim Biotechnologies (OTC: AXIM)
Axim Biotechnologies Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Axim Biotechnologies Company Info
AXIM Biotechnologies, Inc. operates as a biotechnology company, which engages in the development of diagnostic healthcare solutions. Its product categories include Eye Health, SARS-CoV-2, and fentanyl neutralizing antibody test. The company was founded on November 18, 2010 and is headquartered in San Diego, CA.
News & Analysis
3 Marijuana Stocks You Couldn't Pay Me to Buy
These pot stocks are bad news for investors.
3 Marijuana Stocks That Like to Live Life Dangerously
Whether it's a single-drug portfolio or little cash on hand, these drug developers are the definition of risk.
2 Marijuana Stocks That Have Imploded Since August Began
These cannabinoid-based drug developers have recently gone up in smoke.
2 Marijuana Stocks That Turned $10,000 Into $125,000 and $300,000, Respectively
Despite big gains, these pot stocks appear to be headed in diverging directions.
This Marijuana Stock Is Up 2,500%, but It Has 2 Major Red Flags
Despite its big gains, this pot stock remains a going concern.
The Average Marijuana Stock Is Up 332% Over the Past Year
Pot stocks' average return exceeds 23 times the S&P 500's performance over the past year. But is it sustainable?
3 Things You Need to Know About Marijuana Stock Axim Biotechnologies
Axim Biotechnologies was the hottest marijuana stock of 2016, but it's cooled down considerably so far this year. Here's what you need to know about this former highflier.
4 Marijuana Stocks Looking to Combat the Opioid Epidemic
There were 20,101 opioid-related overdose deaths in 2015, compared to zero overdose-related deaths for marijuana that year.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.